Table 3.
Estimated rate ratios (95% confidence intervals) for atrial fibrillation/flutter and bradycardia/conduction blocks, according to randomized treatment group
| Model | Exposure | Atrial Fibrillation or Atrial Fluttera | Bradycardia or Conduction Blocksb |
|---|---|---|---|
| 1 | Spironolactone 12.5 mg vs placebo | 0.09 (0.01–1.04) | 1.56 (0.73–3.34) |
| Spironolactone 25 mg vs placebo | 0.40 (0.03–5.01) | 1.45 (0.61–3.44) | |
| Spironolactone 50 mg vs placebo | 0.89 (0.11–6.96) | 3.00 (0.80–11.20) | |
| 2 | Spironolactone combined vs placebo | 0.47 (0.07–3.21) | 2.04 (0.83–5.05) |
a
Models (independence correlation) included the exposure of interest and study visits.
b
Models (independence correlation) included the exposure of interest, study visits, length of time on dialysis, and current angiotensin converting enzyme inhibitor/angiotensin receptor blocker use.